Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway

Journal of Biomedical Science

Volumn 13, Issue 4, 2006, Pages 535-548

  Huang, Tom Hsun Wei ^a   Li, Yuhao ^a   Razmovski Naumovski, Valentina ^a   Tran, Van Hoan ^a   Li, George Qian ^a   Duke, Colin C ^a   Roufogalis, Basil D ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Gynostemma pentaphyllum; Gypenoside; Nuclear factor kappaB; Peroxisome proliferator activated receptor alpha

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; GYNOSTEMMA PENTAPHYLLUM EXTRACT; GYPENOSIDE; GYPENOSIDE XLIX; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IMMUNOREGULATION; INFLAMMATION; LIPID METABOLISM; MACROPHAGE; MEDICINAL PLANT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; ANIMALS; CELLS, CULTURED; DNA PRIMERS; GENE EXPRESSION REGULATION; GYNOSTEMMA; HUMANS; IMMUNOBLOTTING; INDOLES; LUCIFERASES; MACROPHAGES; NF-KAPPA B; PLANT EXTRACTS; PPAR ALPHA; PROTEIN TRANSPORT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

GYNOSTEMMA PENTAPHYLLUM; MURINAE;

EID: 33745684789     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9076-8     Document Type: Article

References (48)

1. Siebenlist U., Franzoso G. and Brown K., Structure, regulation and function of NF-κB. Ann. Rev. Cell. Biol. 10: 405-455, 1994.
2. Blackwell T.S. and Christman J.W., The role of nuclear factor kappa B in cytokine gene regulation. Am. J. Respir. Cell. Mol. Biol. 17: 3-9, 1997.
3. Blackwell T.S., Lancaster L.H. and Christman J.W., Nuclear factor kappa B: a pivotal role in the systemic response syndrome and new target for therapy. Intensive Care Med. 24: 1131-1138, 1998.
4. Pande V. and Ramos M.J., NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr. Med. Chem. 12: 357-374, 2005.
5. Christman J.W., Sadikot R.T. and Blackwell T.S., The role of nuclear factor-kappa B in pulmonary diseases. Chest 117: 1482-1487, 2000.
6. Collins T., Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab. Invest. 68: 499-508, 1993.
7. Blumert M. and Liu J.L., Jiaogulan in China's "Immortality Herb". Torchlight Publishing Inc., Badger, USA, 1999.
8. Li L., Jiao L. and Lau B.H., Protective effects of gypenosides against oxidative stress in phagocytes, vascular endothelial cells and liver microsomes. Cancer Biother. 8: 263-272, 1993.
9. Chen W.C., Hau D.M., Chen K.T., Wang M.I. and Lin I.H., Protective effects of Gynostemma pentaphyllum in gamma-irradiated mice. Am. J. Chin. Med. 24: 83-92, 1996.
10. Tanner M.A., Bu X., Steimle J.A. and Myers P.R., The direct release of nitric oxide by gypenosides derived from the herb Gynostemma pentaphyllum. Nitric Oxide 3: 359-365, 1999.
11. Zhou Z., Wang Y., Zhou Y. and Zhang S., Effect of gynostemma pentaphyllum mak on carcinomatous conversions of golden hamster cheek pouches induced by dimethylbenzanthracene: a histological study. Chin. Med. J. (Engl) 111: 847-850, 1998.
12. Aktan F., Henness S., Roufogalis B.D. and Ammit A.J., Gypenosides derived from Gynostemma pentaphyllum suppress NO synthesis in in urine macrophages by inhibiting iNOS enzymatic activity and attenuating NF-kappaB-mediated iNOS protein expression. Nitric Oxide 8: 235-242, 2003.
13. Li L. and Lau B., Protection of vascular endothelial cells from hydrogen peroxide induced oxidant injury by gypenosides, saponins of Gynostemma pentaphyllum. Phytother. Res. 7: 299-304, 1993.
14. Guo W.Y. and Wang W.X., Cultivation and utilisation of Gynostemma pentaphyllum. Publishing House of Electronics, Science and Technology University, pp 1-261, 1993.
15. Wang J., Lu Z., Chi J., Wang W., Su M., Kou W., Yu P., Yu J., Chen L., Zhu J.S. and Chang J., Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr. Ther. Res. 58: 964-978, 1997.
16. Coll J.C. and Bowden B.F., The application of vacuum liquid chromatography to the separation of terpene mixtures. J. Nat. Prod. 49: 934-936, 1986.
17. Takemoto T., Arihara S., Nakajima T. and Okuhira M., Studies on the constituents of fructus Momordicae. II. Structure of sapogenin. Yakugaku Zasshi 103: 1155-1166, 1983.
18. Rival Y., Beneteau N., Chapuis V., Taillandier T., Lestienne F., Dupont-Passelaigue E., Patoiseau J.F., Colpaert F.C. and Junquero D., Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. DNA. Cell Biol. 23: 283-292, 2004.
19. Bramlett K.S., Houck K.A., Borchert K.M., Dowless M.S., Kulanthaivel P., Zhang Y., Beyer T.P., Schmidt R., Thomas J.S., Michael L.F., Barr R., Montrose C., Eacho P.I., Cao G. and Burris T.P., A natural product ligand of the oxysterol receptor, liver X receptor. J. Pharmacol. Exp. Ther. 307: 291-296, 2003.
20. Frederiksen K.S., Wulff E.M., Sauerberg P., Mogensen J.P., Jeppesen L. and Fleckner J., Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles. J. Lipid Res. 45: 592-601, 2004.
21. Kehrer J.P., Biswal S.S., La E., Thuillier P., Datta K., Fischer S.M. and Vanden Heuvel J.P., Inhibition of peroxisome-proliferator-activated receptor (PPAR) alpha by MK886. Biochem. J. 356: 899-906, 2001.
22. Sen C.K. and Bagchi D., Regulation of inducible adhesion molecule expression in human endothelial cells by grape seed proanthocyanidin extract. Mol Cell Biochem. 216: 1-7, 2001.
23. Kikuchi T., Hagiwara K., Honda Y., Gomi K., Kobayashi T., Takahashi H., Tokue Y., Watanabe A. and Nukiwa T., Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J. Antimicrob. Chemother. 49: 745-755, 2002.
24. Kim S.H., Kang Y.J., Kim W.J., Woo D.K., Lee Y., Kim D.I., Park Y.B., Kwon B.S., Park J.E. and Lee W.H., TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ. J. 68: 396-399, 2004.
25. Abe A., Kiriyama Y., Hirano M., Miura T., Kamiya H., Harashima H. and Tokumitsu Y., Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur. J. Pharmacol. 436: 7-13, 2002.
26. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G. and Wahli W., Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11: 779-791, 1997.
27. Davies G.F., McFie P.J., Khandelwal R.L. and Roesler W.J., Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes. J. Pharmacol. Exp. Ther. 300: 72-77, 2002.
28. Nho C.W. and O'Dwyer P.J., NF-kappaB activation by the chemopreventive dithiolethione oltipraz is exerted through stimulation of MEKK3 signaling. J. Biol. Chem. 279: 26019-26027, 2004.
29. Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye-binding. Anal. Biochem. 72: 248-254, 1976.
30. Orthner C.L., Rodgers G.M. and Fitzgerald L.A., Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: evidence implicating nuclear factor-kappa B in TF induction by diverse agonists. Blood 86: 436-443, 1995.
31. Marx N., Mackman N., Schonbeck U., Yilmaz N., Hombach V., Libby P. and Plutzky J., PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103: 213-219, 2001.
32. Neve B.P., Corseaux D., Chinetti G., Zawadzki C., Fruchart J.C., Duriez P., Staels B. and Jude B., PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103: 207-212, 2001.
33. Monaco C. and Paleolog E., Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc. Res. 61: 671-682, 2004.
34. Chinetti G., Zawadski C., Fruchart J.C. and Staels B., Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem. Biophys. Res. Commun. 314: 151-158, 2004.
35. Inoue I., Shino K., Noji S., Awata T. and Katayama S., Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 246: 370-374, 1998.
36. Torra I.P., Chinetti G., Duval C., Fruchart J.C. and Staels B., Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr. Opin. Lipidol. 12: 245-254, 2001.
37. Blanquart C., Barbier O., Fruchart J.C., Staels B. and Glineur C., Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid. Biochem. Mol. Biol. 85: 267-273, 2003.
38. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B. and Haegeman G.A., A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv. Exp. Med. Biol. 544: 181-196, 2003.
39. Perez A., Thuillard J.L., Bentzen C.L. and Niesor E.J., Expression of nuclear receptors and apo E secretion during the differentiation of monocytic THP-1 cells into macrophages. Cell. Biol. Toxicol. 19: 95-105, 2003.
40. Kuwahara M., Kawanishi F., Komiya T. and Oshio H., Dammarane saponins of Gynostemma pentaphyllum Makino and isolation of malonylginsenosides-Rb1, -Rd, and malonylgypenoside V. Chem. Pharm. Bull. 37: 135-139, 1989.
41. la Cour B., Molgaard P. and Yi Z., Traditional Chinese medicine in treatment of hyperlipidaemia. J. Ethnopharmacol. 46: 125-129, 1995.
42. Takemoto T., Arihara S., Yoshikawa K., Hino K., Nakajima T. and Okuhira M., Studies on the constituents of cucurbitaceae plants. XII. On the saponin constituents of Gynostemma pentaphyllum Makino (8). Yakugaku Zasshi 104: 1155-1162, 1984.
43. Sun N.J., Woo S.H., Cassady J.M. and Snapka R.M., DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J. Natl. Prod. 61: 362-366, 1998.
44. Francis G.A., Annicotte J.S. and Auwerx J., PPAR-alpha effects on the heart and other vascular tissues. Am. J. Physiol. Heart Circ. Physiol. 285: H1-H9, 2003.
45. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G. and Staels B., Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274: 32048-32054, 1999.
46. Marx N., Sukhova G.K., Collins T., Libby P. and Plutzky J., PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131, 1999.
47. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M. and Kooistra T., Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101: 545-551, 2003.
48. Delerive P., Gervois P., Fruchart J.C. and Staels B., Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275: 36703-36707, 2000.